Prostate cancer has a more precise detection method – most men just don't know it yet

During their annual checkups, many men undergo a PSA test, which can lead to a biopsy if levels are high. The standard prostate cancer detection method has been a transrectal ultrasound (TRUS)-guided biopsy. However, TRUS prostate biopsies are often imprecise, with the ability to detect only 30-41% of cancers.³ This method can miss aggressive cancers or identify low-risk ones that do not require treatment.

Studies have shown that:

Up to 40% of aggressive prostate cancers are undertreated⁴ due to inaccurate risk profiling.

Up to 50% of insignificant prostate cancers are overtreated.⁵

This June, in honor of Men’s Health Month, we aim to highlight how advances in prostate cancer diagnosis can help patients and clinicians choose a personalized approach to treatment using the latest in imaging, digital pathology and AI.

Today, prostate cancer care is shifting toward precision diagnostics that integrate imaging, targeted biopsy, AI-enhanced pathology and personalized planning. And Philips is leading the way.

Here’s how precision becomes practice.

mpMRI with DynaCAD Prostate: High-resolution scans segment suspicious lesions and assign PI-RADS scores to guide targeted action before the biopsy.

MRI/Ultrasound Fusion Biopsy via UroNav: Philips UroNav system fuses MRI and real-time ultrasound, guiding urologists to precisely sample areas of concern identified on mpMRI – improving diagnostic accuracy and confidence in each core taken.⁶

Digital Pathology + AI: Tissues are digitized using scanners and analyzed by the pathologist using AI tools which can bring additional insights such detect patterns and assign Gleason grades with higher consistency than manual reads.

DynaCAD Urology + 3D Visualization: Biopsy data, imaging and pathology are visualized together – enabling cross-disciplinary collaboration and precise treatment planning, including focal therapy where appropriate.

From a patient’s first PSA test to the final treatment decision, Philips is redefining the prostate care journey.

One in six men in the U.S.⁷ will be diagnosed with prostate cancer in their lifetime – yet awareness of advanced diagnostic techniques remains low.

This Men’s Health Month, we urge healthcare leaders, clinicians and patients to learn more about a more precise pathway to prostate cancer detection.

If you’re a patient:

Ask your doctor about mpMRI, fusion-guided biopsy and digital pathology.

If you’re over 50, have a rising PSA or a family history – explore next-gen screening options.

If you’re a clinician:

Discover how Philips’ prostate solution improves detection, diagnostic certainty and care planning.

Contact us here to learn more.